摘要
目的探讨PCT、NT-Pro BNP和D-二聚体水平检测在慢性阻塞性肺疾病患者中的临床价值。方法选取2015年7月至2016年6月期间我院收治的85例慢阻肺患者为观察组,包括稳定期45例、急性加重期40例;同时选取70例同期入院检查为普通肺炎康复者为对照组。结果观察组入院时的NT-Pro BNP、PCT、D-二聚体水平均显著高于对照组(P<0.05);治疗后,观察组各指标水平均显著降低,但仍显著高于对照组,差异有统计学意义(P<0.05)。观察组中,急性加重期患者的血清NT-Pro BNP、PCT、D-二聚体水平均显著高于稳定期患者,差异有统计学意义(P<0.05)。结论对慢阻肺患者的NT-Pro BNP、PCT、D-二聚体水平进行检测,能有效反映其病情程度以及预后。
Objective To explore the clinical value of detection of PCT, NT-Pro BNP and D-Dimer in patients with chronic obstructive pulmonary disease. Methods 85 cases of patients with chronic obstructive pulmonary disease admitted to our hospital from July 2015 to June 2016 were selected as observation group, including 45 cases in stable phase, and 40 cases in acute exacerbation. 70 cases of rehabilitation objects from common pneumonia who received physical examination in our hospital at the same period were selected as control group. Results The levels ofPCT, NT-Pro BNP and D-Dimer of observation group at admission were significantly higher than those of control group （P〈0.05）; The levels ofPCT, NT-Pro BNP and D-Dimer of observation group decreased significantly after treatment, which were still higher than those of control group （P 〈0.05）. In observation group, patients in acute exacerbation had significantly higher PCT, NT-Pro BNP and D-Dimer levels than patients in stable phase （P 〈0.05）. Conclusions The detection of PCT, NT-Pro BNP and D-Dimer can effectively reflect the disease severity and prognosis of patients with chronic obstructive pulmonary disease.
出处
《临床医学工程》
2017年第6期827-828,共2页
Clinical Medicine & Engineering
